CarthroniX has entered into a collaboration with SMC Labs, Japan to explore the therapeutic potential of novel systemic gp130 modulators in animal models of chronic inflammatory and fibrotic disorders. SMC Labs is one of the leading CRO’s in this area specializing in pre-clinical models for drug development. SMC Labs is a pre-clinical CRO development through focused

Heraux, the luxury molecular skincare brand built around the anti-inflammaging properties of our proprietary molecule HX-1, entered the retail space this fall through launches with REVOLVE, The Conservatory and Materiae. REVOLVE is strongly positioned with millennials through influencer marketing, while The Conservatory is a boutique online and brick-and-mortar retailer focused on highly curated lifestyle products.

Despite the challenges 2020 has presented, CX-011 is on schedule to enter clinical trials for mild to moderate osteoarthritis in mid-2021. Following successful scale up and validation, sufficient quantities of the therapeutic candidate were produced under strict Good Manufacturing Practices (GMP) guidelines to support the trial next year. In parallel, CarthroniX received positive regulatory feedback

HEALTH Magazine announced its picks of best new skincare products for 2020, and Heraux Molecular Anti-Inflammaging Serum was included in this elite selection. Highly curated by Heath’s beauty editors, this influential award recognizes the unique technology present in Heraux and the impact this product has in the luxury beauty category.